Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

Breast Cancer Research and Treatment

Volumn 12, Issue 3, 1988, Pages 307-310

  Bertelli, G ^a   Pronzato, P ^a   Amoroso, D ^a   Cusimano, M P ^a   Conte, P F ^a   Montagna, G ^a   Bertolini, S ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

adjuvant endocrine therapy; antithrombin III; plasma lipids; tamoxifen

Indexed keywords

ANTITHROMBIN III; TAMOXIFEN;

AGE; BLOOD LEVEL; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; SIDE EFFECT;

ANTITHROMBIN III; BREAST NEOPLASMS; FEMALE; HUMAN; LIPIDS; MENOPAUSE; MIDDLE AGE; TAMOXIFEN;

EID: 0024272508     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/BF01811244     Document Type: Article

References (12)

1. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
2. Tamoxifen treatment of metastatic breast cancer and antithrombin III levels
3. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
4. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustration of cases
5. Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer
6. Long-term adjuvant therapy with tamoxifen: effects on Sex Hormone Binding Globulin and Antithrombin III
7. DES versus tamoxifen in advanced breast cancer (Letter)
8. Tamoxifen and thrombosis (Letter)
9. Tamoxifen and thromboembolism (Letter)
10. Venous thrombosis as a side effect of tamoxifen treatment